v3.26.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Total revenues   $ 119,371
Cost of revenues   (119,371)
Operating expenses:    
Research and development $ 7,485,813 5,223,589
General and administrative 4,359,663 4,215,908
Total operating expenses 11,845,476 9,439,497
Loss from operations (11,845,476) (9,439,497)
Other income (expense):    
Foreign currency transaction (loss) gain (11,814) 1,591
Interest income, net 270,170 213,975
Research and development incentives   (25,488)
CARES Act employee retention credit   312,753
Other income 125 43
Change in fair value of convertible debt   260,933
Total other income 258,481 763,807
Net loss before income taxes (11,586,995) (8,675,690)
Income tax benefit 506,615 409,114
Net loss applicable to common stockholders $ (11,080,380) $ (8,266,576)
Basic net loss per share (in Dollars per share) $ (2.14) $ (4.98)
Diluted net loss per share (in Dollars per share) $ (2.14) $ (4.98)
Basic weighted average common shares outstanding (in Shares) 5,188,799 1,660,413
Diluted weighted average common shares outstanding (in Shares) 5,188,799 1,660,413
Grant revenue    
Total revenues   $ 119,371